Publications by authors named "G S AHLUWALIA"
Article Synopsis
- Pancreatic cancer is a major health challenge with few effective treatments, largely influenced by its tumor stroma, which consists of various non-cancerous cells and proteins that aid tumor growth and drug resistance.
- Targeting the tumor stroma by remodeling it with phytochemicals—natural compounds found in plants—shows promise for enhancing the effects of chemotherapy and immunotherapy by disrupting the communication between tumor cells and their environment.
- The review discusses how phytochemicals can modify the tumor stroma and explores their potential in combination with existing cancer treatments, emphasizing their anti-cancer, immunomodulatory, and anti-angiogenic properties.
Background: Guidelines recommend targeting decongestion in management of decompensated HF, with lower extremity edema often serving as the clinical target. LECW are seldom used in the acute setting, with a paucity of data on efficacy in HF, despite serving as a cornerstone of chronic lymphedema management.
Primary Objective: Study the efficacy and safety of LECW in acute decompensated HF.
Prosthetic valve endocarditis (PVE) is an uncommon complication after heart valve replacement surgery that can result in increased morbidity and mortality. Current guidelines for management of PVE recommend antibiotic therapy followed by surgical valve replacement. The number of aortic valve replacements is expected to rise in the coming years with the expanded indications for use of transcatheter aortic valve replacement (TAVR) in patients with low, intermediate, and high surgical risk, as well as in patients with a failed aortic bioprosthetic valve.
View Article and Find Full Text PDFArticle Synopsis
- Etrasimod, an oral medication targeting S1P receptors, is being tested for treating moderate-to-severe atopic dermatitis (AD) in adults.
- A phase 2 clinical trial involved 140 participants who were randomly assigned to receive either etrasimod (1 mg or 2 mg) or a placebo for 12 weeks, with the main goal of assessing changes in the Eczema Area and Severity Index (EASI) score.
- While the primary outcome was not achieved, notable improvements were observed in the vIGA-AD scores for the 2 mg etrasimod group compared to placebo, with manageable safety profiles and no serious adverse events reported.